Heron Therapeutics, Inc is a biotechnology business based in the US. Heron Therapeutics shares (HRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Heron Therapeutics employs 223 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Heron Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – HRTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Heron Therapeutics stock price (NASDAQ: HRTX)Use our graph to track the performance of HRTX stocks over time.
Heron Therapeutics shares at a glance
|Latest market close||$13.27|
|52-week range||$12.28 - $22.40|
|50-day moving average||$14.59|
|200-day moving average||$16.53|
|Wall St. target price||$34.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.56|
Buy Heron Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Heron Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Heron Therapeutics price performance over time
|1 week (2021-07-17)||N/A|
|1 month (2021-06-28)||-17.58%|
|3 months (2021-04-28)||-27.88%|
|6 months (2021-01-24)||N/A|
|1 year (2020-07-24)||N/A|
|2 years (2019-07-24)||N/A|
|3 years (2018-07-24)||N/A|
|5 years (2016-07-24)||N/A|
Heron Therapeutics financials
|Revenue TTM||$83.3 million|
|Gross profit TTM||$-120,884,000|
|Return on assets TTM||-35.12%|
|Return on equity TTM||-81.29%|
|Market capitalisation||$1.3 billion|
TTM: trailing 12 months
Shorting Heron Therapeutics shares
There are currently 23.7 million Heron Therapeutics shares held short by investors – that's known as Heron Therapeutics's "short interest". This figure is 1.4% down from 24.0 million last month.
There are a few different ways that this level of interest in shorting Heron Therapeutics shares can be evaluated.
Heron Therapeutics's "short interest ratio" (SIR)
Heron Therapeutics's "short interest ratio" (SIR) is the quantity of Heron Therapeutics shares currently shorted divided by the average quantity of Heron Therapeutics shares traded daily (recently around 1.4 million). Heron Therapeutics's SIR currently stands at 17.31. In other words for every 100,000 Heron Therapeutics shares traded daily on the market, roughly 17310 shares are currently held short.
However Heron Therapeutics's short interest can also be evaluated against the total number of Heron Therapeutics shares, or, against the total number of tradable Heron Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heron Therapeutics's short interest could be expressed as 0.23% of the outstanding shares (for every 100,000 Heron Therapeutics shares in existence, roughly 230 shares are currently held short) or 0.2635% of the tradable shares (for every 100,000 tradable Heron Therapeutics shares, roughly 264 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Heron Therapeutics.
Find out more about how you can short Heron Therapeutics stock.
Heron Therapeutics share dividends
We're not expecting Heron Therapeutics to pay a dividend over the next 12 months.
Have Heron Therapeutics's shares ever split?
Heron Therapeutics's shares were split on a 1:20 basis on 12 January 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heron Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Heron Therapeutics shares which in turn could have impacted Heron Therapeutics's share price.
Heron Therapeutics share price volatility
Over the last 12 months, Heron Therapeutics's shares have ranged in value from as little as $12.28 up to $22.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heron Therapeutics's is 1.3808. This would suggest that Heron Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Heron Therapeutics overview
Heron Therapeutics, Inc. , a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A. P.
Stocks similar to Heron Therapeutics
Heron Therapeutics in the news
JPMorgan upgrades Pacira amid recovery in elective procedures
Heron Therapeutics management to meet virtually with Cantor Fitzgerald
Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™
Frequently asked questionsWhat percentage of Heron Therapeutics is owned by insiders or institutions?
Currently 0.135% of Heron Therapeutics shares are held by insiders and 91.574% by institutions. How many people work for Heron Therapeutics?
Latest data suggests 223 work at Heron Therapeutics. When does the fiscal year end for Heron Therapeutics?
Heron Therapeutics's fiscal year ends in December. Where is Heron Therapeutics based?
Heron Therapeutics's address is: 4242 Campus Point Court, San Diego, CA, United States, 92121 What is Heron Therapeutics's ISIN number?
Heron Therapeutics's international securities identification number is: US4277461020 What is Heron Therapeutics's CUSIP number?
Heron Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00202J104
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy HNC Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert